Newsbenzinga
Evercore ISI Group Downgrades Ultragenyx Pharmaceutical to In-Line, Lowers Price Target to $16
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…